{"filing":{"accession_number":"0001193125-26-400062","cik":"0001994702","ticker":"KYTX","company_name":"Kyverna Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-24","report_date":"2026-09-24","primary_document":"kytx-20260924.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526400062/kytx-20260924.htm"},"events":[{"id":34692,"run_id":31937,"accession_number":"0001193125-26-400062","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Kyverna announced positive one-year durability data from its registrational trials KYSA-8 (stiff person syndrome) and KYSA-6 (generalized myasthenia gravis) for miv-cel, with sustained clinical responses, favorable safety profiles, and a rolling BLA submission on track for Q4 2026. While this is clinical trial data disclosure rather than a traditional earnings release, it represents a material operational and strategic milestone for a late-stage clinical company—the data directly supports regulatory approval prospects and the company's pipeline advancement, which would affect a reasonable investor's assessment of the registrant's prospects.","company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","filing_date":"2026-09-24","form":"8-K","submitted_at":null,"items":[{"id":38508,"accession_number":"0001193125-26-400062","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Kyverna announced positive one-year durability data from its registrational trials KYSA-8 (stiff person syndrome) and KYSA-6 (generalized myasthenia gravis) for miv-cel, with sustained clinical responses, favorable safety profiles, and a rolling BLA submission on track for Q4 2026. While this is clinical trial data disclosure rather than a traditional earnings release, it represents a material operational and strategic milestone for a late-stage clinical company—the data directly supports regulatory approval prospects and the company's pipeline advancement, which would affect a reasonable investor's assessment of the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T10:04:12.849785+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38508,"accession_number":"0001193125-26-400062","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Kyverna announced positive one-year durability data from its registrational trials KYSA-8 (stiff person syndrome) and KYSA-6 (generalized myasthenia gravis) for miv-cel, with sustained clinical responses, favorable safety profiles, and a rolling BLA submission on track for Q4 2026. While this is clinical trial data disclosure rather than a traditional earnings release, it represents a material operational and strategic milestone for a late-stage clinical company—the data directly supports regulatory approval prospects and the company's pipeline advancement, which would affect a reasonable investor's assessment of the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T10:04:12.849785+00:00","company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","filing_date":"2026-09-24"}]}